Teva Pharmaceuticals 因违反反回扣法规和价格操纵而达成 $450M 和解。 Teva Pharmaceuticals settles $450M for Anti-Kickback Statute violations and price-fixing.

Teva制药公司将支付4.5亿美元,解决关于违反《反Kickback规约》的指控。 Teva Pharmaceuticals will pay $450 million to settle allegations of violating the Anti-Kickback Statute. 据称，从 2006 年到 2017 年，该公司在提高价格的同时，承担了 Medicare 患者为其多发性硬化症药物 Copaxone 的共付额。 From 2006 to 2017, the company allegedly covered Medicare patients' copays for its multiple sclerosis drug Copaxone while raising its price. 此外,Teva承认与其他非专利制造商为几种药物定价。 Additionally, Teva admitted to price-fixing with other generic manufacturers for several drugs. 和解包括2.25亿美元的刑事处罚,并解决多重回扣方案。 The settlement includes a $225 million criminal penalty and resolves multiple kickback schemes.